Vaximm (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- January 15, 2023
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $20,000,000
Company Info
- Founding Year
- 2010
- Traction
- Vaximm has successfully completed multiple clinical trials demonstrating the efficacy of its lead product candidate, leading to partnerships with major pharmaceutical companies.
- Founders
- Dr. Rainer H. Schmid, Dr. Michael H. Schmitt
- Company Description
- Vaximm is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary platform to create therapeutic vaccines that stimulate the immune system to target and destroy cancer cells.
- Market
- Healthcare
- Location
- Tübingen, Baden-Württemberg, Germany